SALT LAKE CITY / Apr 24, 2025 / Business Wire / Varex Imaging Corporation (Nasdaq: VREX) today announced that it will report unaudited financial results for the second quarter of fiscal year 2025, following the close of regular trading on Thursday, May 8, 2025. The earnings news release will be followed by a conference call at 3:00 pm Mountain Time that day.
This call will be webcast live and can be accessed at the company's website at www.vareximaging.com/investor-relations/. Investors can also access this conference call at 877-524-8416 from anywhere in the U.S. or 412-902-1028 from non-U.S. locations. The webcast of this call will be archived on the company’s website and a replay of the call will be available from May 8th through May 22nd at 877-660-6853 from anywhere in the U.S. or 201-612-7415 from non-U.S. locations. The replay conference call access code is 13753373. The listen-only webcast link is: https://event.choruscall.com/mediaframe/webcast.html?webcastid=lX6SZW6F.
About Varex
Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and other image processing solutions that are key components of X-ray imaging systems, as well as X-ray imaging systems for industrial applications. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate the company’s X-ray sources, digital detectors, connecting devices and imaging software in their systems to detect, diagnose, protect and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,300 people located in North America, Europe, and Asia. For more information visit www.vareximaging.com.
Last Trade: | US$8.45 |
Daily Change: | -0.26 -2.99 |
Daily Volume: | 285,241 |
Market Cap: | US$348.390M |
February 03, 2025 December 23, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load